The role of high-dose chemotherapy in the management of advanced ovarian cancer.
Despite advances in terms of chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor. The issue of dose intensity remains controversial in treatment of patients with advanced ovarian cancer. This review focuses on the issues of dose intensity, particularly platinum dose intensity with regard to treatment of advanced ovarian cancer. Specific issues addressed include 1) results of the current generation of randomized trials of dose intensity in ovarian cancer; 2) the use of combination platinum strategies, focusing on attempts at paclitaxol dose intensification in the setting of advanced ovarian cancer; and 3) approaches utilizing high-dose chemotherapy both with bone marrow and progenitor self-support and the use of multiple cycle high-dose chemotherapy in patients with advanced disease.
Saint Vincent's Hospital, Dublin, Ireland.
D
D
Fennelly
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D017239:Paclitaxel; D002945:Cisplatin